Dr Martin Hall, Head of Life Sciences here at Hardman & Co was today featured as part of the Daily Telegraph article "AstraZeneca dividend under threat, analysts warn".
Julia Bradshaw states:
AstraZeneca will need to cut its dividend because the pharmaceutical giant does not have enough cash to pay for it and will almost certainly need to raise more money if no action is taken, according to an independent analyst.
Martin Hall, of Hardman & Co, said AstraZeneca’s operational cash flow – the money it generates from daily business operations – following the expiration of patents on several top-selling drugs, notably Nexium, Losec and Seroquel.
Read our exclusive report by clicking the button at the top of the page.
The full Daily Telegraph article can be found here.
